Akcea gains as Novartis exercises option for CV risk reduction therapy

Akcea Therapeutics Inc. (NASDAQ:AKCA) added $4.57 (17%) to $31.91 on Feb. 25 after Novartis AG (NYSE:NVS; SIX:NOVN) exercised an option to license its antisense APOA1 inhibitor in a

Read the full 283 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE